Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (460)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05471674 | Neoadjuvant Anti-PD1 in HCC | completed | Phase 2 | 20 | Dr Tan-to CHEUNGOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT03980288 | 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 | completed | Phase 1 | 6 | Zhejiang UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02438436 |
| completed |
| Phase 3 |
| 180 |
| Guangxi Medical UniversityOTHER |
| 1 |
| Jan 30, 2023 |
| clinicaltrials |
| NCT02654028 | Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection(AT/HCC) | completed | N/A | 618 | Guangxi Medical UniversityOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT02435433 | A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein(REACH-2) | completed | Phase 3 | 399 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 20, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03867916 | Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients | completed | N/A | 106 | University of California, San FranciscoOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05681234 | Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma | completed | N/A | 30 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT03648073 | [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 12 | University of Alabama at BirminghamOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05225207 | A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants | completed | — | 658 | Eisai Korea Inc.INDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT01642186 | Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04763707 | Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis | completed | — | 87 | Sohag UniversityOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT02794805 | Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | completed | Phase 2 | 74 | Meridian Bioscience, Inc.INDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT01116804 | Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 36 | University Hospital, GhentOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT05643833 | Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | completed | — | 3,769 | Zhejiang UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02013492 | Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | completed | Early Phase 1 | 1 | William CarsonOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04172714 | Low-dose Y90 Treatment Planning for HCC | completed | N/A | 30 | Emory UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT04310709 | Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma(RENOBATE) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03233360 | Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry(INSIGHT) | completed | — | 2,533 | National Cancer Centre, SingaporeOTHER | 9 | Dec 5, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00956930 | Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery | completed | Phase 2 | 45 | Northwestern UniversityOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT03379844 | HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients | completed | Phase 2 | 30 | UMC UtrechtOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01180959 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | completed | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05047146 | The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt | completed | — | 530 | Sadat City UniversityOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04780802 | Balloon Assisted Transarterial Therapy for Hepatocellular Carcinoma | completed | N/A | 10 | Chinese University of Hong KongOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01176604 | Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma | completed | N/A | 299 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02489422 | Programs To Support You During Chemotherapy(PRO-YOU) | completed | N/A | 44 | Wake Forest University Health SciencesOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02128958 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 78 | Can-Fite BioPharmaINDUSTRY | 5 | Oct 4, 2022 | clinicaltrials |
| NCT04420026 | Study of Automatic Image Fusion of a CT Volume With Ultrasound During Percutaneous Ablation Treatment of Hepatic Tumors(IAT) | completed | N/A | 44 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT00740753 | Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option(Y-90HDE) | completed | N/A | 339 | OHSU Knight Cancer InstituteOTHER | 0 | Sep 30, 2022 | clinicaltrials |
| NCT02072356 | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery | completed | Early Phase 1 | 290 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT02702401 | Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) | completed | Phase 3 | 413 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 29, 2022 | clinicaltrials |
| NCT02582918 | Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5 | completed | N/A | 2,871 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT02024087 | Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 21 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05545046 | Predictive Model for Pain After TACE | completed | — | 228 | Yantai Yuhuangding HospitalOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05535998 | TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | completed | — | 743 | Yunfei YuanOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05307926 | Postoperative Adjuvant Therapy of HCC Based on PD-1 | completed | — | 573 | Chen XiaopingOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT05178524 | Clinical Study on BIFICO Accelerating Postoperative Liver Function Recovery in Patients With Hepatocellular Carcinoma | completed | N/A | 180 | Tongji HospitalOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05111795 | Holmium-166 Retrospective Collection of Real-World Data(RECORD) | completed | — | 146 | Terumo Europe N.V.INDUSTRY | 7 | Aug 30, 2022 | clinicaltrials |
| NCT04295330 | Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy | completed | N/A | 260 | West China HospitalOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05517239 | Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment(PEACH) | completed | Phase 2 | 32 | Yonsei UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT02115373 | c-Met Second-Line Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 66 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03232593 | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | completed | — | 1,758 | Hoffmann-La RocheINDUSTRY | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02141906 | A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin | completed | Phase 2 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05502458 | Effect of Propofol and Desflurane on Nucleic Acid of Liver Circulating Tumor | completed | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT00530010 | Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | — | 500 | Northwestern UniversityOTHER | 1 | Aug 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 1, 2023source: clinicaltrials